Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom

Phase 2SKY-0515Positive

AI Analysis

Summary

Skyhawk Therapeutics announced expansion of its global pivotal FALCON-HD trial for SKY-0515 in Huntington's Disease to the United States, Canada, and the United Kingdom, with over 175 patients enrolled across more than twenty sites. Phase 1/2 enrollment is complete and the drug has demonstrated good tolerability with twelve months of patient data.

Clinical Trial Data

Phase

Phase 1/2

Patients

175

Outcome Details

Phase 1/2 enrollment complete, generally well tolerated with twelve months of patient data

Importance:6/10

Sentiment:

0.60

Huntington's DiseaseFALCON-HD trialGlobal expansionClinical trial enrollmentPhase 1/2

Related Companies

$GBCYD $UTHR

Read the original article

Published by PR Newswire Biotech on July 14, 2026 12:17 PM

Read Original